FDA OKs Akorn allergic rhinitis nasal spray

Akron (AKRX +12.2%) is up on almost 40% higher volume in concert with most of its generic drug maker brethren. The FDA just approved its Azelastine Hydrochloride Nasal Spray, 0.15% for the relief of symptoms of seasonal allergic rhinitis.

Per IQVIA, the U.S. market is ~$18M.

https://seekingalpha.com/news/3494680-fda-oks-akorn-allergic-rhinitis-nasal-spray